Advanced Cell Technology Inc has announced the dosing of the first patients in each of its two Phase 1/2 clinical trials for eye disorders using retinal pigment epithelial cells derived from human embryonic stem cells (hESCs). ---Subscribe to MedNous to access this article--- Regenerative Medicine
